Figure 1. Regulatory classification of biological age test categories against market, as at 17 August 2026. Cells record the ...
The Group's gross profit increased by 40.6 % period-over-period to RMB 1,371.3 million, with a gross profit margin of 37.0 % ...
Ir Dr Ted Suen, Chief Executive Officer of ASTRI (left) and Professor Stephen Cheung Yan-leung, President of Saint Francis ...
ATG-201 is a CD19 targeting bispecific TCE incorporating steric hindrance masking technology, designed to eliminate ...
Following the European launch of Omlyclo ® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength ...
New Orbitrap Isora workflow integrates mass spectrometry, Vanquish Duo UHPLC System and Isotope Discoverer Software to bring ...
In November 2025, Hanmi received IND (Investigational New Drug) clearance from the U.S. FDA (Food and Drug Administration) to ...
Rznomics Inc. (KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, ...
AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 ...
PD-L1/4-1BB bispecific antibody secures Priority Review and could become the world’s first approved therapy directly ...
CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral ...
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), announced the continued participation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results